This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.
Top Research Reports for Today: GILD, DOW, MET & More
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), Dow Chemical (DOW) and MetLife (MET).
Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus
by Zacks Equity Research
Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.
After Gilead Earnings, Buy These Biotech Stocks
by Madeleine Johnson
Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.
Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.
Alphabet, Boston Beer, Apple and Gilead Sciences highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Alphabet, Boston Beer, Apple and Gilead Sciences highlighted as Zacks Bull and Bear of the Day
Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update
by Arpita Dutt
Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.
Apple Sells Fewer iPhones, Gilead Misses Sales
by Mark Vickery
Apple, Inc. (AAPL) shares are falling more than 1% in after-market trading following its fiscal Q2 earnings report.
Gilead (GILD) Misses Q1 Earnings and Revenue Estimates, Stock Drops
by Madeleine Johnson
Gilead Sciences (GILD) just released its first quarter fiscal 2017 financial results, posting earnings of $2.23 per share and revenues of $6.5 billion.
Radius Health (RDUS) Q1 Earnings: What's in Store?
by Zacks Equity Research
Radius Health, Inc. (RDUS) is scheduled to report first-quarter 2017 financial results on May 3.
What's in Store for Zoetis (ZTS) Stock This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.
What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.
Geron (GERN) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Geron Corporation (GERN) is expected to report first-quarter 2017 results next week
Apple, Facebook and Gilead Sciences are part of Zacks Earnings Preview
by Zacks Equity Research
Apple, Facebook and Gilead Sciences are part of Zacks Earnings Preview
Is Intercept (ICPT) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Is Intercept (ICPT) Poised for a Beat this Earnings Season?
What to Expect from Keryx (KERX) Stock This Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2017 results on May 4.
Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased
Why Gilead (GILD) Might Surprise This Earnings Season
by Zacks Equity Research
Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Tech Sector's Strong Earnings Power
by Sheraz Mian
Technology sector's Q1 results are coming from a diverse cross-section of companies.
BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017
What to Expect from Prothena (PRTA) This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.
What's in Store for Merck (MRK) this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
by Zacks Equity Research
Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.